Intellia Therapeutics (NTLA) Stock Forecast & Price Target

$13.71 -0.14 (-1.01%)

Closing price 05/7/2026 04:00 PM Eastern

Extended Trading

$13.67 -0.04 (-0.29%)

As of 05/7/2026 07:59 PM Eastern

Compare

Intellia Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 23 Analyst Ratings

Sell
3

Hold
10

Buy
10

Based on 23 Wall Street analysts who have issued ratings for Intellia Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 23 analysts, 3 have given a sell rating, 10 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for NTLA.

Consensus Price Target

$20.09
46.51% Upside

According to the 23 analysts' twelve-month price targets for Intellia Therapeutics, the average price target is $20.09. The highest price target for NTLA is $58.00, while the lowest price target for NTLA is $5.00. The average price target represents a forecasted upside of 46.51% from the current price of $13.71.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NTLA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NTLA Analyst Ratings Over Time

Type	Current Forecast 5/8/25 to 5/8/26	1 Month Ago 4/8/25 to 4/8/26	3 Months Ago 2/7/25 to 2/7/26	1 Year Ago 5/8/24 to 5/8/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	12 Buy rating(s)
Hold	10 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)	6 Hold rating(s)
Sell	3 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$20.09	$19.59	$17.48	$36.68
Forecasted Upside	46.51% Upside	41.25% Upside	42.31% Upside	343.05% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

NTLA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NTLA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Intellia Therapeutics Stock vs. The Competition

Type	Intellia Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.35	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	46.51% Upside	875.85% Upside	14.95% Upside
News Sentiment Rating	Neutral News See Recent NTLA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/28/2026	The Goldman Sachs Group 3 of 5 stars	Salveen Richter 4 of 5 stars	Boost Target	Sell	$8.00 ➝ $9.00	-30.84%
4/28/2026	Citigroup 4 of 5 stars		Reiterated Rating	Outperform
4/28/2026	Canaccord Genuity Group 4 of 5 stars	Whitney Ijem 5 of 5 stars	Boost Target	Buy	$48.00 ➝ $58.00	+332.35%
4/28/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Silvan Turkcan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Outperform	$28.00 ➝ $30.00	+119.97%
4/27/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$35.00	+164.85%
4/27/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$11.00 ➝ $15.00	+13.51%
4/27/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jack Allen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$7.00 ➝ $13.00	-6.58%
4/27/2026	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geulah Livshits Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$27.00 ➝ $30.00	+115.59%
4/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
3/25/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
Get the Latest News and Ratings for NTLA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
3/4/2026	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debanjana Chatterjee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$29.00	+113.24%
3/3/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$9.00 ➝ $15.00	+7.17%
3/3/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yanan Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$12.00 ➝ $15.00	+6.61%
3/3/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mitchell S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$25.00 ➝ $30.00	+94.30%
3/2/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral
3/2/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform
1/28/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$25.00	+79.53%
11/12/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
11/11/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Miller Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform ➝ In-Line	$17.00 ➝ $8.00	-17.78%
11/7/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$27.00	+174.98%
11/7/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$24.00 ➝ $14.00	+45.12%
11/7/2025	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Nierengarten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$9.00 ➝ $7.00	-28.83%
11/7/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Cheng Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underweight	$12.00 ➝ $5.00	-59.42%
10/28/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$14.50	-1.96%
10/28/2025	Tudor Pickering Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$14.50	-1.96%
10/27/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/10/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$70.00 ➝ $50.00	+334.78%
9/11/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$80.00 ➝ $64.00	+218.09%
6/24/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$65.00 ➝ $65.00	+156.11%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:34 AM ET.

NTLA Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Intellia Therapeutics is $20.09, with a high forecast of $58.00 and a low forecast of $5.00.
: 23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 sell ratings, 10 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NTLA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NTLA, but not buy additional shares or sell existing shares.
: According to analysts, Intellia Therapeutics's stock has a predicted upside of 46.51% based on their 12-month stock forecasts.
: Over the previous 90 days, Intellia Therapeutics's stock had 3 upgrades by analysts.
: Intellia Therapeutics has been rated by research analysts at Bank of America, Canaccord Genuity Group, Chardan Capital, Citigroup, Citizens Jmp, HC Wainwright, JonesTrading, Leerink Partners, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, The Goldman Sachs Group, Truist Financial, Weiss Ratings, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Intellia Therapeutics more than other "medical" companies. The consensus rating score for Intellia Therapeutics is 2.35 while the average consensus rating score for "medical" companies is 2.30. Learn more on how NTLA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Intellia Therapeutics Recommendations

This page (NASDAQ:NTLA) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NTLA Analyst Ratings Over Time

NTLA Analyst Recommendations By Month

NTLA Price Targets by Month

Intellia Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

NTLA Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Intellia Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NTLA Analyst Ratings Over Time

NTLA Analyst Recommendations By Month

NTLA Price Targets by Month

Intellia Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

NTLA Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Intellia Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools